An observational study in Myelofibrosis, sponsored by Center for International Blood and Marrow Transplant Research. Recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-08-30.
Sponsored by Center for International Blood and Marrow Transplant Research · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.
Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 11th largest by planned enrollment of the 35 observational ones that give a count, is one of 14 that started in 2016, is one of 35 observational ones, reaches primary completion later than 26 of the 104 other live ones, and was the 300th registered.
628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.
Browse Primary Myelofibrosis studies →70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:
John Mascarenhas · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 28 more countries
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18–75 · Healthy volunteers
Damora Therapeutics · Sites in United States, Australia
Ages 18+
University of Utah · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 55 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
454 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 167 · Phase 2 220 · Phase 3 45
First in 1992; this study’s year is marked. 14 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 125 across 73 observational studies indexed under Primary Myelofibrosis.
Median enrollment 40 across the 388 interventional studies, 153 across the 35 observational. Of the 328 that completed or were terminated, 152 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
134 of 454 have an industry lead sponsor. The 10 most frequent:
Center for International Blood and Marrow Transplant Research is the lead sponsor of 32 studies on the registry; 8 are open to participants now.
Center for International Blood and Marrow Transplant Research has 3 studies filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
40 of the studies in Primary Myelofibrosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06479135Phase 3Kartos Therapeutics, Inc.Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | 2026-12-31 |
| NCT06468033Phase 3PharmaEssentiaP1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk | 2027-11-18 |
| NCT02934477Center for International Blood and Marrow Transplant ResearchProspective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis | 2026-11 |
| NCT01973881University of Michigan Rogel Cancer CenterQuantitative MRI for Myelofibrosis | 2026-12 |
| NCT06414681University of Kansas Medical CenterCombination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined | 2026-12 |
Add all 40 to your calendar (.ics) → With an account.
Among the 454 studies in Primary Myelofibrosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
Patients with primary MF (PMF), post-essential thrombocythemia (ET) MF, or post-polycythemia vera (PV) MF, with intermediate-2 or high-risk disease as determined by the DIPSS, and aged ≥55 at the time of DIPSS assessment are eligible for this study. For the allogeneic HCT arm of the HLA-Matched Donor HCT Study, donors must be either 6/6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins), OR an 8/8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donors; both peripheral blood stem cells and bone marrow grafts are allowed, and all conditioning regimen intensities and graph versus host disease (GVHD) prophylaxis regimens are allowed. For the Haploidentical Donor Study, donors must be haploidentical.
This study will target accrual of 650 patients receiving alloHCT, including approximately 225 receiving myeloablative conditioning. Participating centers are expected to provide data for approximately 2,400 patients to form the non-HCT historical control cohort.
Patients with primary MF (PMF), post-essential thrombocythemia (ET) MF, or post-polycythemia vera (PV) MF, with intermediate-2 or high-risk disease as determined by the DIPSS, and aged ≥55 at the time of DIPSS assessment are eligible for this study. For the alloHCT arm of the HLA-Matched Donor HCT Study, donors must be either 6/6 HLA-matched related donors, defined by Class I (HLA-A and -B) intermediate resolution or high resolution DNA-based typing and Class II (HLA-DRBI) at high resolution DNA-based typing (but not monozygotic twins), OR an 8/8 HLA-A, -B, -C, and -DRB1 at high resolution DNA-based typing matched unrelated donors; both peripheral blood stem cells and bone marrow grafts are allowed, and all conditioning regimen intensities and GVHD prophylaxis regimens are allowed. For the Haploidentical Donor Study, donors must be haploidentical.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients fulfilling the following criteria will be eligible for inclusion in the study:
For the alloHCT arm:
Exclusion Criteria:
Patients with the following criteria will be ineligible for entry into the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing alloHCT in a US transplant center and reported to the CIBMTR
Other: Hematopoietic Stem Cell Transplant
Historical non-transplant controls collected from 14 US academic centers. Centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
Compare five year survival
Compare the five-year survival probabilities from DIPSS assessment between the two study arms: alloHCT recipients (arm 1) and non-HCT therapies (ruxolitinib / best supportive care) recipients (arm 2).
Time frame: Five years post transplant
Compare leukemia-free survival
Compare leukemia-free survival at five years from DIPSS assessment date to the date of progression to AML or death from any cause, whichever comes first. Two co-secondary analyses will be conducted, one for all alloHCT patients versus Arm 2 and one for the subset of patients receiving MAC prior to alloHCT versus Arm 2. Observation is censored at the date of last follow-up for patients known to be alive without leukemia. Progression to AML is defined as \>20% leukemia blasts in bone marrow or in the peripheral blood.
Time frame: Five years post transplant
Cumulative incidences of chronic GVHD
Occurrence of symptoms in any organ system fulfilling the criteria of chronic GVHD. Patients are censored at last follow-up or second transplant.
Time frame: Five years post transplant
Cumulative incidences of acute GVHD
Occurrence of grade II, III, and/or IV skin, gastrointestinal, or liver abnormalities fulfilling the Consensus criteria of acute GVHD. Patients are censored at last follow-up or second transplant.
Time frame: Five years post transplant
Cumulative incidence of treatment related mortality
Death from any cause in the first 28 days post-transplantation, irrespective of relapse status. Death beyond day +28 will only be considered transplant-related if the disease is in remission. This event will be summarized as a cumulative incidence estimate with relapse/persistence as the competing risk.
Time frame: Five years post transplant
The impact of certain patient, disease and HCT related factors on survival in the alloHCT arm.
Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 years vs. \>= 65 years, disease duration and DIPSS on overall survival in the alloHCT arm. The time to event in the analyses will start at the time of transplant.
Time frame: Five years post transplant
The impact of certain patient, disease and HCT related factors on leukemia free survival in the alloHCT arm.
Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs. \>= 65 years), disease duration and DIPSS on leukemia free survival in the alloHCT arm. The time to event in the analyses will start at the time of transplant.
Time frame: Five years post transplant
The impact of certain patient, disease and HCT related factors on hematopoietic recovery in the alloHCT arm.
Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>=65 years), disease duration and DIPSS on hematopoietic recovery in the alloHCT arm. The time to event in the analyses will start at the time of transplant.
Time frame: Five years post transplant
The impact of certain patient, disease and HCT related factors on acute and chronic GVHD in the alloHCT arm.
Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>= 65 years), disease duration and DIPSS on acute and chronic GVHD in the alloHCT arm. The time to event in the analyses will start at the time of transplant.
Time frame: Five years post transplant
The impact of certain patient, disease and HCT related factors on treatment related mortality in the alloHCT arm.
Evaluation of the impact of response to ruxolitinib therapy, patient age (\<65 vs \>=65 years), disease duration, and DIPSS on treatment related mortality in the alloHCT arm. The time to event in the analyses will start at the time of transplant.
Time frame: Five years post transplant.
The impact of certain patient, disease and HCT related factors on relapse.
Evaluation of the impact of response to ruxolitinib therapy, patient age (65 vs \>=65 years), disease duration and DIPSS on relapse in the alloHCT arm. The time to event in the analyses will start at the time of transplant.
Time frame: Five years post transplant.
Plan to share: Undecided
The record gives a start of Nov 2016, a primary completion of Nov 2026 and a completion of Oct 2027. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Center for International Blood and Marrow Transplant Research